Statutory payment rate on UK pharma sales to double

The UK government has doubled the rate that pharma companies must repay on the sales of newer products to the National Health Service (NHS) under the statutory scheme for branded medicines in the second half of 2025, to a record 31.3%.

Following a consultation, the government has opted to raise the statutory scheme payment rate for newer branded medicines from 15.5% to 31.3% of subject companies' NHS sales, starting the beginning of next month. 

This new rate brings the annual average in the statutory scheme to 23.4% over the whole of 2025. The statutory scheme headline payment percentage will be set at 24.3% in 2026, and 26% per cent in 2027.